InVivo to end Inspire trial despite meeting primary endpoint, plans new study

January 3, 2018 By Fink Densford Leave a Comment

InVivo Therapeutics (NSDQ:NVIV) today released updated results from the Inspire study of its neuro-spinal scaffold but said that it would not be reopening enrollment, which it paused last July, and is instead looking to a new randomized controlled trial to supplement the results.

The Cambridge, Mass.-based company said that 43.8% of the 16 living patients in the trial who had been implanted with the scaffold had reached the primary endpoint of an AIS grade improvement at six months. The objective performance criterion for he study had been a 25% AIS conversion rate, InVivo said.

The last patient to reach the primary endpoint was assessed to be AIS C motor incomplete at six months, with some motor function detected on the sacral level. Of the total seven Inspire patients who had AIS improvements at six months, five improved from complete AIS A SCI ratings to sensory incomplete AIS B SCI ratings, and two patients improved from complete AIS A SCI ratings to motor incomplete AIS C SCI ratings.

A total of two of the five patients assessed at AIS B at six months showed improvements to AIS C ratings at 1 and 2 years respectively, InVivo Therapeutics said.

The company halted enrollment last July after a third patient died shortly after being discharged from the hospital after implantation. While the death was deemed to be unrelated to the neuro-spinal scaffold or the implantation procedure, the company said it was initiating a temporary enrollment halt while it explored possible trial changes with the FDA.

In continued discussions with the FDA, InVivo said it has proposed a randomized controlled trial to supplement its existing evidence, and does not plan to re-open enrollment in the trial but will provide “additional clarity on its clinical path forward in the second quarter of 2018.”

“I am pleased to report the latest AIS conversion results from Inspire. Inspire demonstrated the surgical feasibility of neuro-spinal scaffold implantation and produced encouraging data on AIS conversions at six months compared to the objective performance criterion and natural history reported in the literature. We remain in discussions with the FDA regarding the clinical path forward in support of a Humanitarian Device Exemption filing. We are working diligently to provide clarity as expeditiously as possible as we evaluate various strategic and financing options. I look forward to providing more details on our proposed randomized controlled study in the second quarter of 2018,” acting CEO Richard Toselli said in a press release.

Last August, InVivo said it was laying off nearly 40% of its workforce, pausing its Inspire clinical trial and cutting two R&D programs as it tries to get its a pivotal study back on track.

DeviceTalks Boston is Bigger and Better than Ever!

Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.

DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Early Registration is now open.

Key Surgical acquires Encompas Unlimited
Key Surgical recently announced that it has acquired Encompas Unlimited to expand its endoscopy product offerings. The financial details of the deal were not disclosed. This is the second acquisition that Key Surgical has completed after merging with Interlock Medizintechnik last year. Emcompas specializes in manufacturing, assembling and distribution a variety of endoscopy accessories and […]
Here are the top 5 medtech stories of mid-2018
A growing U.S. trade war with China and other countries casts a pall on medtech — and U.S. business in general — in mid-2018. The landscape of the medical device industry continues to evolve, though. There’s a major corporate spinout in the works, as well as a mega-merger that apparently was not to be. Read […]
Medtech stories we missed this week: July 13, 2018
From Angiodroid receiving CE Mark approval to Masimo launching its vital signs app, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Angiodroid wins CE Mark for Angiopulse IABP Angiodroid announced in a July 11 press releasethat it has received CE Mark approval for its AngioPulse intra-aortic balloon pump […]
OCTANe wraps up Ophthalmology Technology Summit
OCTANe recently hosted its annual Ophthalmology Technology Summit (OTS) where hundreds of industry leaders, investors and physicians attended to learn about ophthalmology trends and innovations. The company says that the event say significant growth this year with over 400 attendees at the conference, which is a 35% increase in attendance, year-over-year. oTS is designed to […]
Who’s afraid of the big, bad PMAs?
PMAs at FDA are often a scary process for medical devices developers. But that doesn’t have to be the case, according to Michael Drues, a regulatory consultant based outside Boston who has worked with both medical device companies and FDA. There are many myths around premarket approval, such as the idea that PMAs always require […]
Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Gerresheimer plans to acquire Swiss medical technology company Sensile Medical and its array of liquid drug delivery devices. The buyout is a perfect fit in Gerresheimer’s portfolio, the company explained, since it will boost Gerresheimer’s drug delivery offerings and add new digital and electronic capabilities into the mix. Get the full story at our sister site, Drug Delivery […]
GW Plastics promotes new leaders to executive team
GW Plastics recently announced that it has appointed three new leaders to its executive team. Cathy Tempesta has been appointed to VP of human resources at GW Plastics. She has been with the company for 15 years as the director of human resources. Tempesta will be responsible for bringing the best practices to GW Plastics’s […]
Schott to acquire Primoceler and its glass micro-bonding packaging tech
Schott (Mainz, Germany) recently announced that it has agreed to acquire Primoceler Oy and its hermetic packaging portfolio with glass micro-bonding technology. The Primoceler technology out of Finland is meant to enable the manufacture of vacuum-tight, ultra-miniature, ultra-reliable medical implants. Financial terms of the deal, announced Monday, were not disclosed. Primoceler’s glass bonding method is based […]
Dune Medical debuts waste-saving surgical probe
Dune Medical Devices has designed a reposable version of its MarginProbe radiofrequency spectropscopy device, which can help surgeons identify remaining cancer cells in real time during a lumpectomy. The updated MarginProbe has a reusable cable and handle and a single-use attachable probe. It has the potential to reduce waste burden of the MarginProbe up to […]
Medline buys Canadian stroke rehab device maker NeuroGym
Medline has acquired physical therapy and rehabilitation equipment maker NeuroGym Technologies of Ottawa, Ontario. NeuroGym’s equipment is designed for people who have had a stroke or other traumatic brain injury, spinal cord injury, chronic neurological conditions such as multiple sclerosis, balance issues and/or the need for fall prevention therapy. The equipment requires the patient to initiate […]
Viant expands leadership team with former Medtronic, Integer executives
The newly rebranded Viant is expanding its leadership team after completing the acquisition of Advanced Surgical and Orthopedics. Viant, formerly known as MedPlast, has appointed former Medtronic executive Sean Crowley to chief operating officer. The company has also appointed former Integer executive Declan Smyth to group president of Advanced Surgical and Orthopedics. Crowley has more […]